UBS Group’s Moleculin Biotech MBRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-170
| Closed | -$7.81K | – | 10795 |
|
|
2026
Q1 | $7.81K | Sell |
170
-123
| -42% | -$8.14K | ﹤0.01% | 8549 |
|
|
2025
Q4 | $19.4K | Buy |
293
+285
| +3,563% | +$53.1K | ﹤0.01% | 7805 |
|
|
2025
Q3 | $2.1K | Sell |
8
-8
| -50% | -$2.16K | ﹤0.01% | 9223 |
|
|
2025
Q2 | $2.41K | Buy |
+16
| New | +$6.56K | ﹤0.01% | 9472 |
|
|
2025
Q1 | – | Sell |
-18
| Closed | -$15.2K | – | 10526 |
|
|
2024
Q4 | $15.2K | Buy |
+18
| New | +$21.8K | ﹤0.01% | 8055 |
|
|
2023
Q4 | – | Hold |
0
| – | -$85 | – | 9659 |
|
|
2023
Q3 | – | Hold |
0
| – | – | – | 8920 |
|
|
2023
Q1 | – | Sell |
-1
| Closed | -$11.9K | – | 10037 |
|
|
2022
Q4 | $11.9K | Hold |
1
| – | – | ﹤0.01% | 8333 |
|
|
2022
Q3 | $11K | Buy |
+1
| New | +$11.6K | ﹤0.01% | 8308 |
|
|
2022
Q2 | – | Hold |
0
| – | – | – | 9583 |
|
|
2021
Q4 | – | Hold |
0
| – | -$4K | – | 10514 |
|
|
2021
Q3 | – | Hold |
0
| – | – | – | 8654 |
|
|
2021
Q2 | – | Hold |
0
| – | – | – | 8676 |
|
|
2021
Q1 | – | Sell |
-1
| Closed | -$29K | – | 9289 |
|
|
2020
Q4 | $29K | Hold |
1
| – | – | ﹤0.01% | 6661 |
|
|
2020
Q3 | $51K | Hold |
1
| – | – | ﹤0.01% | 5634 |
|
|
2020
Q2 | $46K | Hold |
1
| – | – | ﹤0.01% | 5922 |
|
|
2020
Q1 | $21K | Buy |
+1
| New | +$34.1K | ﹤0.01% | 6465 |
|
|
2019
Q4 | – | Hold |
0
| – | – | – | 6939 |
|
|
2019
Q3 | – | Hold |
0
| – | – | – | 7052 |
|
|
2019
Q2 | – | Hold |
0
| – | – | – | 8035 |
|
|
2019
Q1 | – | Hold |
0
| – | -$1K | – | 7976 |
|
|
2018
Q4 | – | Hold |
0
| – | – | – | 7904 |
|
|
2018
Q3 | – | Hold |
0
| – | – | – | 7407 |
|
|
2018
Q1 | – | Hold |
0
| – | -$4K | – | 8025 |
|
|
2017
Q4 | – | Hold |
0
| – | – | – | 7470 |
|
|
2017
Q3 | – | Hold |
0
| – | – | – | 7221 |
|
|
2017
Q2 | – | Hold |
0
| – | – | – | 6111 |
|
|
2017
Q1 | – | Hold |
0
| – | – | – | 6819 |
|
|
2016
Q4 | – | Hold |
0
| – | – | – | 7241 |
|
|
2016
Q3 | – | Hold |
0
| – | – | – | 6559 |
|
|
2016
Q2 | – | Hold |
0
| – | – | – | 6900 |
|
Other funds holding MBRX
UBS Group's MBRX Position: Q2 2026 in Review
UBS Group sold out of Moleculin Biotech (MBRX) in Q2 2026, closing a stake of 170 shares — an estimated $7.81K sold.
UBS Group first reported a position in MBRX in Q1 2020 and held it in 11 quarters. The position peaked at $51K in Q3 2020. 15 funds tracked by Wall St. Rank hold MBRX as of Q2 2026.
- UBS Group reported no remaining Moleculin Biotech position as of Q2 2026 after selling out during the quarter.
- UBS Group sold 170 Moleculin Biotech shares in Q2 2026, an estimated $7.81K.
- UBS Group first reported a position in Moleculin Biotech in Q1 2020 and held it in 11 quarters.
- UBS Group's Moleculin Biotech position peaked at $51K in Q3 2020.
- 15 funds tracked by Wall St. Rank held Moleculin Biotech as of Q2 2026.
Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.